Peptide vaccines have weak ability to provoke host immune responses. The weak immunogenicity of the peptide vaccine can be handled with the technique of multi-epitopes peptide design [71 (link),72 (link)]. In multi-epitopes peptide-design phase, immunodominant epitopes were linked to each other [73 (link)]. All the selected screened epitopes were linked with the Gly-Pro-Gly-Pro-Gly (GPGPG) linkers to build an immunopotent multi-epitopes peptide vaccine. Furthermore, the vaccine was linked with the highly immunopotent cholera toxin B adjuvant (CTB) for the enhancement of the vaccine immunogenicity [74 (link),75 (link)]. The adjuvant binds to the monoganglioside GM1 receptor and is capable of stimulating cytokines, interferone, cellular and humoral immunity [75 (link)]. The adjuvant is used in vaccine design against cancer, tuberculosis and influenza [76 (link)].
Free full text: Click here